This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer

This study is currently recruiting participants.
See Contacts and Locations
Verified April 2017 by Memorial Sloan Kettering Cancer Center
Sponsor:
Collaborator:
Amgen
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01312857
First received: March 8, 2011
Last updated: April 3, 2017
Last verified: April 2017
  Purpose
The purpose of this study is to see if Panitumumab plus the other treatments will increase the time of remission. Remission means that there is no sign of the cancer.

Condition Intervention Phase
Metastatic Colorectal Cancer Drug: panitumumab Drug: Randomization to No Panitumumab Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Phase II Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer

Resource links provided by NLM:


Further study details as provided by Memorial Sloan Kettering Cancer Center:

Primary Outcome Measures:
  • to determine if panitumumab with Hepatic Arterial Infusion (HAI) in combination with systemic chemotherapy can increase the recurrence free survival (RFS) for colorectal cancer patients with resected liver metastases [ Time Frame: 2 years ]

Secondary Outcome Measures:
  • to assess toxicity as per the NCI Common Toxicity Criteria [ Time Frame: Day 1 of each cycle ]
    Toxicities will be recorded as adverse events on the Adverse Event case report form and must be graded using The National Cancer Institute's Common Toxicity Criteria (CTC)version 4.0 with the exception of skin- or nail-related toxicities, which must be graded using CTC version 3.0 with modifications

  • to determine survival [ Time Frame: 2 years ]
  • to analyze tumor tissue for predictive biomarkers [ Time Frame: 2 years ]
    (such as NRAS, BRAF, PIK3CA, AKT1 and MEK1), and correlate with patient progression and survival following therapy.


Estimated Enrollment: 78
Actual Study Start Date: March 2011
Estimated Study Completion Date: March 2018
Estimated Primary Completion Date: March 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Randomization to panitumumab
Patients whose liver metastases have been completely resected will be randomized Arm A will receive Panitumumab in addition to HAI FUDR/Dexamethasone plus systemic CPT-11/5FU/LV
Drug: panitumumab

All patients receive HAI FUDR (0.12 mg/kg/day X kg X pump volume) / pump flow rate and Dexamethasone flat dose of 25 mg on days 1.

All patients receive CPT-11 (150 mg/m2 IV over 30 min to an hour), Leucovorin (400 mg/m2 IV, over 30 min to an hour) and 5FU (1000 mg/m2/day continuous infusion over two days) on days 15 and 29 Randomization to panitumumab 6 mg/kg day 15 and 29 Each cycle repeats every 36 days for a total of 6 cycles

Experimental: Randomization to No Panitumumab
Patients whose liver metastases have been completely resected will be randomized and patients randomized to Arm B will receive HAI FUDR/Dex plus systemic CPT-11/5FU/LV alone.
Drug: Randomization to No Panitumumab

All patients receive HAI FUDR (0.12 mg/kg/day X kg X pump volume) / pump flow rate and Dexamethasone flat dose of 25 mg on days 1.

All patients receive CPT-11 (150 mg/m2 IV over 30 min to an hour), Leucovorin (400 mg/m2 IV, over 30 min to an hour) and 5FU (1000 mg/m2/day continuous infusion over two days) on days 15 and 29 Randomization (to no panitumumab) Each cycle repeats every 36 days for a total of 6 cycles


  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • History of histologically confirmed colorectal adenocarcinoma metastatic to the liver with no clinical or radiographic evidence of extrahepatic disease. Confirmation of diagnosis must be performed at MSKCC.
  • Completely resected hepatic metastases without current evidence of other metastatic disease.
  • Lab values ≤ 14 days prior to registration:
  • WBC ≥ 3.0 K/uL
  • ANC > 1.5 K/uL
  • Platelets ≥ 100,000/uL
  • Creatinine <1.5 mg/dL
  • HGB ≥ 9 gm/dL Renal function (≤ 14 days prior to registration).
  • Creatinine ≤1.5 mg/dL or creatinine clearance ≥ 50 mL/min calculated by the

Cockcroft-Gault method as follows:

  • Male creatinine clearance = (140 -age in years) x (weight in Kg) / (serum Cr in mg/dl x 72)
  • Female creatinine clearance = (140 - age in years) x (weight in Kg) x 0.85 / (serum Cr in mg/dl x 72) (use of creatinine clearance per protocol based on chemotherapy regimen) Hepatic function, as follows: (≤ 14 days prior to registration)
  • Aspartate aminotransferase (AST) (≤ 5 x ULN)
  • Alanine aminotransferase (ALT) (≤ 5 x ULN)
  • Total Bilirubin ≤ 1.5 mg/dl
  • Magnesium ≥ lower limit of normal (≤ 48 hours prior to registration.)
  • Calcium ≥ lower limit of normal (≤ 48 hours prior to registration.)
  • Prior chemotherapy is acceptable if last dose given ≥ 3 weeks prior to registration to this study. [Note: no chemotherapy to be given after resection of liver lesions prior to treatment on this study.]
  • Any investigational agent is acceptable if administered ≤ 30 days before registration
  • KPS ≥ 60% (ECOG (or Karnofsky) performance status (preferably 0 or 1/≥ 60% for Karnofsky)
  • Histologically confirmed all RAS wild type.
  • Paraffin-embedded tumor tissue obtained from the primary tumor or metastasis

Exclusion Criteria:

  • Patients < 18 years of age.
  • Prior radiation to the liver (Prior radiation therapy to the pelvis is acceptable if completed at least 4 weeks prior to registration.)
  • Active infection, ascites, hepatic encephalopathy.
  • Prior treatment with HAI FUDR.
  • Patients who have had prior anti EGFR antibody therapy inhibitors and who have not responded to this treatment will be excluded. However, patients who have responded to prior anti-EGFR therapy are eligible.)
  • Female patients who are pregnant or lactating - or planning to become pregnant within 6 months after the end of the treatment (female patients of child-bearing potential must have negative pregnancy test ≤ 72 hours before registration).
  • If a patient has any serious medical problems which may preclude receiving this type of treatment.
  • Patients with current evidence of hepatitis A, B, C (ie, active hepatitis)
  • Patients with history or known presence of primary CNS tumors, seizures not well controlled with standard medical therapy, or history of stroke will also be excluded.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to Panitumumab.
  • Serious or non-healing active wound, ulcer, or bone fracture.
  • History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan.
  • Patients who have a diagnosis of Gilbert's disease.
  • History of other malignancy, except:
  • Malignancy treated with curative intent and with no known active disease present for ≥ 3 years prior to registration and felt to be at low risk for recurrence by the treating physician
  • Adequately treated non-melanomatous skin cancer or lentigo maligna without evidence of disease
  • Adequately treated cervical carcinoma in situ without evidence of disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01312857

Contacts
Contact: Nancy Kemeny, MD 646-888-4180
Contact: Michael D'Angelica, MD 212-639-3226

Locations
United States, New Jersey
Memorial Sloan Kettering Basking Ridge Recruiting
Basking Ridge, New Jersey, United States, 07920
Contact: Nancy Kemeny, MD    646-888-4180      
Memorial Sloan Kettering Monmouth Recruiting
Middletown, New Jersey, United States, 07748
Contact: Nancy Kemeny, MD    646-888-4180      
United States, New York
Memorial Sloan Kettering Commack Recruiting
Commack, New York, United States, 11725
Contact: Nancy Kemeny, MD, PhD    646-888-4180      
Memorial Sloan Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Contact: Nancy Kemeny, MD    646-888-4180      
Contact: Michael D'Angelica, MD    212-639-3226      
Principal Investigator: Nancy Kemeny, MD         
Memorial Sloan Kettering Rockville Centre Recruiting
Rockville Centre, New York, United States, 11570
Contact: Nancy Kemeny, MD    646-888-4180      
Memorial Sloan Kettering Westchester Recruiting
West Harrison, New York, United States, 10604
Contact: Nancy Kemeny, MD    646-888-4180      
Contact: Michael D'Angelica, MD    212-639-3226      
Principal Investigator: Nancy Kemeny, MD         
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
Amgen
Investigators
Principal Investigator: Nancy Kemeny, MD Memorial Sloan Kettering Cancer Center
  More Information

Additional Information:
Responsible Party: Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT01312857     History of Changes
Other Study ID Numbers: 10-137
Study First Received: March 8, 2011
Last Updated: April 3, 2017

Keywords provided by Memorial Sloan Kettering Cancer Center:
colon
rectal
liver
AMG 954 (Panitumumab)
DEXAMETHASONE
FLOXURIDINE
FLUOROURACIL
IRINOTECAN (CPT-11) CAMPTOSAR
LEUCOVORIN
10-137

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Dexamethasone acetate
Dexamethasone
Irinotecan
BB 1101
Antibodies, Monoclonal
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 21, 2017